Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Stem cell-derived pancreatic islet cell progenitors

            Therapeutic Area: Endocrinology Product Name: PEC-Encap

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: ViaCyte Inc

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement August 05, 2020

            Details:

            Parties have signed an agreement covering the next phase of their ongoing collaboration focused on the development of ViaCyte's Encaptra® Cell Delivery System enabled by proprietary Gore advanced material technologies.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ent001

            Therapeutic Area: Endocrinology Product Name: Ent001

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Sofinnova Partners

            Deal Size: $33.1 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing July 28, 2020

            Details:

            Proceeds to be used for clinical proof-of-concept for lead product Ent001 (IGFBP3/TMEM219 inhibitor) for type 1 diabetes, gastrointestinal diseases and progress pipeline assets.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Endocrinology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Peptide

            Partner/Sponsor/Collaborator: Frazier Healthcare Partners

            Deal Size: $34.6 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing July 27, 2020

            Details:

            Proceeds of the financing will support MBX as it advances its preclinical pipeline of peptide therapeutic candidates directed at clinically validated molecular targets.

            University of Pittsburgh

            • Deals

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): GPX-002

            Therapeutic Area: Endocrinology Product Name: GPX-002

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: National Institutes of Health

            Deal Size: $2.5 million Upfront Cash: Undisclosed

            Deal Type: Funding July 21, 2020

            Details:

            The grant will assist Dr. Gittes’s development for his research project titled, “Alpha Cell Conversion to Beta Cells in Non-human Primates” and will build upon his accumulating groundbreaking gene therapy work toward finding a cure for diabetes.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): siRNA

            Therapeutic Area: Endocrinology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 15, 2020

            Details:

            The company has identified a promising modified delivery vector ready for possible pre-clinical experiments based on stable siRNA (small interfering ribonucleic acid) incorporation within the delivery vehicle.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PTH(1-34)

            Therapeutic Area: Endocrinology Product Name: PTH(1-34)

            Highest Development Status: Preclinical Product Type: Peptide

            Partner/Sponsor/Collaborator: National Institutes of Health

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Funding July 07, 2020

            Details:

            The grant was conferred for the development of a long acting parathyroid hormone – PTH(1-34) – that can be administered once-weekly for treatment of hypo-parathyroidism.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Peptide

            Therapeutic Area: Endocrinology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Peptide

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 26, 2020

            Details:

            The application is directed to new peptides from the company’s two peptide classes, and their use in the treatment of diabetes and its complications.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): GL0034

            Therapeutic Area: Endocrinology Product Name: GL0034

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 24, 2020

            Details:

            Pre-clinical performance of GL0034 was assessed in a highly relevant type 2 diabetes db/db mouse model. The NCE demonstrated significant outcomes on various diabetic parameters and a marked and meaningful reduction in triglyceride levels.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AZP-3601

            Therapeutic Area: Endocrinology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Peptide

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 02, 2020

            Details:

            Amolyt Pharma is developing AZP-3601, a parathyroid hormone analog specifically designed for the treatment of hypoparathyroidism, as well as AZP-3404, a peptide with a new and unique mechanism of action on fat and glucose metabolism.